The model, called the TyrRS cascade, argues that this enzyme functions as a nutrient-sensitive switch that partitions the neuron’s 24-hour cycle into two incompatible workloads. During waking hours, when dietary tyrosine is abundant, TyrRS stays locked in its canonical cytoplasmic configuration, prioritizing protein synthesis and activity-dependent transcription. During the overnight fast, when tyrosine levels fall to their nadir, TyrRS is freed to translocate into the nucleus, where it orchestrates genome maintenance through three coordinated streams. The authors contend that the crucial variable is not the average level of TyrRS activity but the amplitude of its daily oscillation, a claim with far-reaching implications for how aging and neurodegeneration are measured and treated.

The first of the three streams is the most experimentally established. Nuclear TyrRS binds directly to PARP1, the master sensor of DNA strand breaks, and lifts the enzyme out of its auto-inhibited conformation, licensing the poly-ADP-ribose reactions that recruit repair machinery to damaged sites. This discovery, originally made by Sajish and Schimmel, revealed that a tRNA synthetase could act as a potent activator of a canonical DNA damage response pathway. The cascade model adds a temporal dimension: PARP1 activity follows a feeding-entrained rhythm peaking at the wake-to-sleep transition, and its catalytic substrate NAD+ oscillates through the CLOCK:BMAL1-NAMPT axis, so the acute repair arm is naturally gated to the sleep window.

But PARP1 has a second, opposing role. During wakefulness, the same enzyme serves as a transcriptional coactivator, partnering with ERK2 at the promoters of immediate early genes such as c-fos, Arc, and Npas4 to support memory encoding. The cascade model predicts that in young, healthy neurons, the overnight repair program resolves the day’s damage load, leaving PARP1 free for this morning shift. In aging neurons, however, an increasing fraction of PARP1 becomes sequestered at unresolved break sites throughout the waking day, blunting activity-dependent transcription. This produces the bidirectional cognitive phenotype seen in early Alzheimer’s disease: impaired consolidation of old memories and impaired encoding of new ones, arising from a single enzyme caught in the wrong job at the wrong time.

The second stream involves chromatin maintenance. TyrRS interacts with TRIM28/KAP1, a scaffolding protein that recruits the HP1-alpha and SUV39H1 machinery to deposit repressive H3K9me3 marks at transposable element loci. When retroelements escape this silencing in the aging brain, they trigger chronic interferon signaling and cGAS-STING activation, a sterile inflammatory cascade well documented in aged tissue. The authors describe this stream as temporally integrated rather than overtly rhythmic, a permissive arm whose erosion proceeds over hours to days and whose collapse presents as a progressive drift in chromatin state rather than a loss of rhythm.

The third stream is the most speculative and the most intriguing. Nuclear TyrRS acts as a positive transcription factor at the LIN9 promoter, and LIN9 is the central scaffolding subunit of the MuvB core of the DREAM complex, which represses a conserved archive of 67 DNA repair genes including BRCA1, FANCD2, RAD51, and OGG1. The model proposes that DREAM occupancy oscillates across the day: high during waking, when silencing the repair archive protects it from interference by active transcription, and low during sleep, when the archive can be cleanly expressed. The informational currency here is the peak-to-trough excursion itself. A neuron whose DREAM oscillation flattens loses both the protective daytime peak and the permissive nighttime trough, even if the average repression level looks unchanged.

This distinction between amplitude and mean carries a sharp methodological warning. Bulk-tissue assays that report average DREAM activity will, in the presence of a flattened oscillation, return a number that appears pathologically elevated while actually describing a system that has lost its signaling capacity. The authors call this the frozen-intermediate state, and they argue that the elevated DREAM activity scores observed in Alzheimer’s tissue reflect collapsed amplitude rather than deepened repression. Demonstrating target engagement for any future therapy, they contend, will require phase-resolved measurement rather than single-timepoint sampling, a requirement that current experimental practice rarely meets.

Aging, in this framework, delivers a double hit. First, serum tyrosine rises modestly with age, roughly 15 to 25 percent across cohort studies, which may compress the daily excursion in tyrosine availability enough to narrow the window in which TyrRS is freed for nuclear duty. Second, circadian amplitude flattens through convergent mechanisms: loss of suprachiasmatic nucleus neurons, weakened CLOCK:BMAL1 transcription, retinal ganglion cell decline, and pineal calcification. Neither insult alone may be decisive, but together they trap the cascade in its intermediate state. The damage then feeds forward: unrepaired lesions and derepressed retroelements activate inflammatory pathways that further disrupt clock gene expression, accelerating the collapse in a self-amplifying cycle that helps explain why neurodegeneration, once begun, progresses so relentlessly.

Perhaps the most striking move in the paper is its dialogue with Maiken Nedergaard’s recent oscillatory account of sleep. During NREM sleep, the major neuromodulators reorganize into synchronized infraslow oscillations with a period of roughly 50 seconds, driving vasomotion that powers glymphatic clearance of amyloid-beta and tau. The authors propose that this extracellular oscillator and the intracellular 24-hour TyrRS cascade are complementary arms of a single sleep-dependent maintenance program: one clears the neuropil, the other repairs the genome. Both fail through amplitude collapse, and both respond perversely to sustained activation. Zolpidem, which suppresses norepinephrine oscillation, reduces glymphatic clearance by about 30 percent despite producing more sleep. By analogy, sustained-release TyrRS modulators would flatten the very rhythm they aim to restore, making pulsatile, phase-aligned dosing the operative therapeutic principle for both arms.

The translational consequences are concrete. The NIH’s Accelerating Medicines Partnership has nominated YARS1 as an Alzheimer’s-relevant target, and the cascade model specifies a narrow design space: agents should transiently shift TyrRS toward its nuclear-competent state without impairing aminoacylation, concentrate exposure in a presleep pulse, avoid sustained-release pharmacology, and preserve NAD+ availability. Early trials should enroll on flattened amplitude biomarkers rather than amyloid status alone, and combined restoration of intracellular repair and extracellular clearance should outperform single-arm intervention. The authors are candid about limitations: the three streams have never been demonstrated to operate together in vivo, and the TyrRS-LIN9 axis in mature neurons awaits direct confirmation. But if phase-resolved experiments validate the framework, neurodegeneration may need to be reconceived, not as a failure of repair capacity, but as a failure of scheduling, one that a well-timed pill might begin to correct.

Subject of Research: Circadian regulation of neuronal DNA repair through the tyrosyl-tRNA synthetase signaling cascade and its collapse in aging and neurodegeneration

Article Title: The TyrRS cascade: circadian gating of neuronal DNA repair and its collapse in aging

Article References: Mathew, S., Seiden, D., Ingram, D. K., & Smith, W. K. (2026). The TyrRS cascade: circadian gating of neuronal DNA repair and its collapse in aging. GeroScience. https://doi.org/10.1007/s11357-026-02532-0

Image Credits: AI Generated

DOI: 10.1007/s11357-026-02532-0

Keywords: TyrRS, YARS1, circadian rhythm, DNA repair, PARP1, DREAM complex, neurodegeneration, Alzheimer's disease, glymphatic clearance, aging, chronotherapy, sleep